Full Press Release Details
Biodexa Pharmaceuticals PLC
("Biodexa" or the "Company")
Receipt of NASDAQ Delisting Determination
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a
clinical-stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announced
today that on June 14, 2023, it received a Staff determination letter (the "Letter") from the Listing Qualifications Department
of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company of the Staff's determination to delist the Company's
securities from The Nasdaq Capital Market because the Company's securities have had a closing bid price below $0.10 for ten consecutive
trading days, which triggers a notice of delisting pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the "$0.10 Rule").
In addition to the $0.10 Rule delisting notice, the Company also currently fails to satisfy the requirement that the closing bid
price of its securities remain at $1.00 or higher as required by Nasdaq Listing Rule 5810(c)(3)(A) (the "Minimum Bid Price
Rule"). The Company has received a period of 180 calendar days to return to compliance with the Minimum Bid Price Rule, which compliance
period expires on July 31, 2023. If the Company's securities fail to regain compliance with the Minimum Bid Price Rule, Nasdaq will
have an additional basis for delisting the securities.
Pursuant to the Letter, unless the Company requests
an appeal of the Letter, trading of the Company's American depositary shares ("ADSs") will be suspended at the opening
of business on June 23, 2023, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"),
which will remove the Company's securities from listing and registration on the Nasdaq Stock Market.
The Company plans to appeal the Staff's
determination to a Hearings Panel (the "Panel"). A hearing request will stay the suspension of the Company's securities
and the filing of the Form 25-NSE pending the Panel's decision.
The Company intends to monitor the closing bid
price of its ADSs and may, if appropriate, consider implementing available options to regain compliance with the minimum bid price requirements
under the Nasdaq Listing Rules for continued listing on Nasdaq.
Biodexa Pharmaceuticals PLC
Stephen Stamp, CEO, CFO
Tel: +44 (0)29 2048 0180
Edison Group (US Investor Relations)
Tel: +1 (860) 573 9637
Email: afactor@edisongroup.com
About Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (listed on NASDAQ:
BDRX) is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain.
The Company's lead candidate, MTX110, is being studied in aggressive rare/orphan brain cancer indications including recurrent glioblastoma
and diffuse midline glioma.
MTX110 is a liquid formulation of the histone
deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced
delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding
Biodexa is supported by three proprietary drug
delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa's headquarters and
R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.
Forward-Looking Statements
Certain statements in this announcement may constitute
"forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States. Such statements
are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management's
belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should
be considered forward-looking statements.
Reference should be made to those documents that
Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated
by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained
in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement.
All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary
statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation
to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.